ISSAR Pharma

Home       About Us

Formed as a company driven by pharmaceutical innovation to address
the unmet healthcare needs, ISSAR pharmaceuticals Pvt. Ltd. was
founded in 1995 by Mr Ramakrishna Isanaka.

About Us

ISSAR’S purpose lies in the development of new technologies at an affordable price to improve quality of life for Indian population. With over 25 years of experience and prime focus in Research and Development, ISSAR’S dedicated team of experts are proud to have developed India’s first ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’S  commitment has also led to the development of their second New Chemical Entity called Xylentra®, which is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.Recently, ISSAR has also developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis and Sepsis.

The future holds an extensive place for peptides as safe and efficient therapeutics with excellent diagnostic, preventive and curative properties. ISSAR is the only pharmaceutical company working as a purely peptide manufacturing technology based company with an FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft. located in Genome valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automated technology for synthesis and purification of peptides, producing highest standards of purity of up to 99.5% by continued process optimization.

ISSAR uses Solid phase peptide synthesis as the technology of choice with a long-standing expertise in custom peptide synthesis at all scales. With our emphasis on quality, safety and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.

To be a global leader in peptide drug discovery for improving patients’ quality of lives.

To design and deliver novel peptide based drugs for the unmet healthcare needs and making it affordable for better health outcomes through collaboration.

Innovation: We believe in encouraging discovery and development of new peptide based products by taking continous initiatives towards technology absorption, adaptation and innovation at our R&D centre to bring forward life changing treatment approaches to improve patients’ quality of life.

Commitment: We are highly committed to our goals and vision, for the development of new formulations to introduce first to market products, optimise drug delivery performance , product stability, with an objective to reach the unmet healthcare needs of patients.

Transparency: We follow a highly transparent nature of work culture followed by a strict conduct of ethics providing all reliable information for our consumers with a formulation development strategy based on in depth study of patents, scientific literature, compendia information, Critical Quality Attributes (CQA) and Quality Target Product Profiles (QTPP) of the respective drug delivery system and nature of the molecule.

Responsibility: We maintain great standards of quality following all fundamental parts of pharmaceutical product development and are accountable througout the process of development, testing and commercialisation of new chemical entities invented by us.

ISSAR Pharma Pvt. Ltd. was founded by Mr. Ramakrishna Reddy Isanaka in 1995, with a prime focus in research and development of New Chemical Entities (NCE) for various unmet medical needs. His interest towards pharmaceuticals and biotechnology developed while he lived in the United States for over 30 years after completion of his M.S from City University of New York. He then decided to begin biotechnology research in his homeland, India, and later Co-Founded Shantha Biotechnics in 1993, at a time when Bio-technology was new to India.

Mr.Isanaka solely established ISSAR Pharma in 1995, a period during which India was majorly into manufacturing generic drugs. Mr.Isanaka was keen on research and indigenous development of peptide-based drug molecules in India, leading to the development of India’s first ever peptide molecule, Melgain for the treatment of Vitiligo in 2004.

His efforts in research and development led to the advancement of ISSAR Pharma as the first ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in development of indigenous molecules with 2 successfully commercialized products, 7 plus patents to his credit and over 6 commercially viable products under development.